Newest FDA-approved opioid use disorder drug enters the market with flexible dosing

The newest approved opioid use disorder drug is leaning on its flexible dosing schedule and injection site convenience to gain traction. Braeburn’s Brixadi can be administered as a weekly dose, but also as a monthly dose like its competitors. It also counts the drug’s lack of refrigeration needed and ability for injections at multiple sites on the body as additional differentiators.

“A weekly dose is important in this category in particular because clinicians like to see patients on a frequent basis especially early in the diagnosis or upon relapse,” Braeburn president and CEO Mike Derkacz said.

Preview

来源: EndPoints

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP

LOG IN

BECOME A PREMIUM SUBSCRIBER

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。